2 weeks Ago By ABMN Staff
Roivant Sciences Ltd. ( NASDAQ:ROIV – Get Free Report ) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company.
The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $17.39. Several analysts have weighed in on the company.
Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Thursday, September 19th.
Piper Sandler lifted their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th.
Finally, Bank of America lifted their target price on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th.
Read Our Latest Research Report on ROIV Insider Transactions at Roivant Sciences Institutional Investors Weigh In On Roivant Sciences A number of institutional investors have recently bought and sold shares of the business. nVerses Capital LLC purchased a new stake in shares of Roivant Sciences in the second quarter worth approximately $34,000. Point72 Hong Kong Ltd purchased a new stake in Roivant Sciences in the 2nd quarter worth approximately $36,000.
Quarry LP acquired a new stake in shares of Roivant Sciences during the 2nd quarter valued at $53,000. Acadian Asset Management LLC purchased a new position in shares of Roivant Sciences during the 1st quarter valued at $72,000. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Roivant Sciences in the second quarter worth $101,000.
64.76% of the stock is currently owned by institutional investors and hedge funds. Roivant Sciences Trading Down 0.
8 % NASDAQ:ROIV opened at $11.48 on Wednesday. Roivant Sciences has a 12-month low of $8.
24 and a 12-month high of $13.24. The firm has a market capitalization of $8.
48 billion, a P/E ratio of 2.27 and a beta of 1.25.
The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.
91. The business has a 50 day simple moving average of $11.50 and a 200 day simple moving average of $11.
08. Roivant Sciences ( NASDAQ:ROIV – Get Free Report ) last announced its earnings results on Thursday, August 8th. The company reported $0.
12 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.33.
The firm had revenue of $55.10 million for the quarter, compared to the consensus estimate of $30.72 million.
Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%.
The firm’s revenue for the quarter was up 155.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.
38) EPS. Equities research analysts predict that Roivant Sciences will post -1.14 EPS for the current year.
About Roivant Sciences ( Get Free Report Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter ..
